Background: The neuropeptide calcitonin gene-related peptide (CGRP) plays a key role in migraine. CGRP gene expression involves an enhancer that is active in neurons, yet inactive in glia. In this report, we analyze epigenetic modifications that allow enhancer activation in glia. Methods: DNA methylation and histone acetylation states were measured in rat and human-model cell lines and primary cultures of rat trigeminal ganglia glia. The functional consequence of altering the chromatin state was determined by quantitative measurements of both calcitonin (CT) and CGRP mRNAs. Results: A hypermethylated CpG island flanking the enhancer was identified in glia and non-expressing cell lines. In addition, the chromatin was hypoacetylated. Treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine induced CT mRNA $30-fold in glial cultures. Treatment with a histone deacetylase inhibitor alone had little effect; however, the combination of inhibitors yielded a synergistic $80-fold increase in CT and $threefold increase in CGRP mRNA. Treated glia contained CT precursor (pro-CT) immunoreactivity. Conclusions: Epigenetic modulation is sufficient to induce the CGRP gene in glia. Because the CGRP gene is systemically activated by inflammatory conditions, this suggests that glial pro-CT may be an unexplored biomarker during migraine.
Introduction
Elevated levels of the neuropeptide calcitonin generelated peptide (CGRP) have been linked to the onset and pathology of migraine (1) (2) (3) (4) . The significance of CGRP in migraine has been demonstrated by induction of migraine-like headaches following CGRP injection (5) and effective migraine relief by CGRP receptor antagonists (6) (7) (8) . CGRP is encoded by the CALCA gene, which yields both CGRP and the hormone calcitonin (CT) as alternative splice products (9) . CALCA expression is normally primarily restricted to endocrine and neuronal cells and is not normally expressed by glia. Given the increasing evidence that glia play important roles in pain conditions (10, 11) , including possibly migraine (12) (13) (14) , we have investigated the mechanisms that normally prevent expression of the CGRP gene in glia.
Neuronal expression of the CALCA gene has been attributed to an 18-bp enhancer located about 1 kb upstream of the transcription start site. This enhancer is sufficient for cell-specific CALCA gene expression in neuronal-like cell lines and trigeminal ganglia neurons (15) (16) (17) . The enhancer is activated by the bHLH-Zip upstream stimulatory factor (USF) (17) (18) (19) . USF can also act with the forkhead protein FoxA2 to synergistically activate the enhancer, although FoxA2 is not present in trigeminal ganglia (19) . We previously proposed that the combination of a relatively high USF level in neurons and a less-than-optimal USF-binding site in the 18-bp enhancer could contribute to its neural-specificity (17) . However, a similar level of USF1 and USF2 was detected in the CALCAexpressing CA77 cell line as in the non-expressing Rat2 cell line (KY Park and AF Russo, unpublished observation). This indicates that additional mechanisms must restrict CALCA gene expression.
Epigenetic modifications involving DNA methylation and histone deacetylation are well-established mechanisms for repressing gene expression (20, 21) . DNA methylation at cytosines within a cluster of CpG dinucleotides called a CpG island results in chromatin compaction and gene silencing. Previous studies reported a CpG island extending from about À1.8 kb into exon 1 of the human CALCA gene (22, 23) . However, correlation of the methylation status with CALCA gene expression was not clear; some ''negative'' tissues and cell lines (liver and small-cell lung carcinomas) actually express CALCA, and the restriction enzymes used only recognized a subset of CpG sites. In addition to CpG methylation, deacetylation of histones, especially H3 and H4, by histone deacetylases (HDACs) is associated with transcriptional repression (24) . To date, histone modifications on the CALCA gene have not been reported.
In this report, we provide evidence that reversal of epigenetic silencing is sufficient for CALCA gene expression. Using rat and human cell lines as model systems, we found that a CpG island near the 18-bp enhancer was hypomethylated in expressing cells, while hypermethylated in non-expressing cells. In addition, histone acetylation was much higher in the CALCA geneexpressing cells than in non-expressing cells. A DNA methylation inhibitor 5-aza-2'-deoxycytidine (Aza-dC) (25) induced the CALCA gene in both non-expressing cell lines and primary glial cultures, demonstrating that DNA methylation represses CALCA expression. Addition of the histone deacetylase inhibitor trichostatin A (TSA) to Aza-dC-treated glial cultures further induced the CALCA gene. These findings are the first evidence that the CALCA gene can be induced in glia.
Methods

Cell lines and trigeminal ganglia glial cultures
Culture conditions for CA77, TT and NCI-H460 cells have been described (18, 19) . Rat2 cell line (ATCC, Manassas, VA, USA) was maintained in Dulbecco's Modified Eagle's Medium (high glucose), 10% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 mg/ml) at 37 C in 5% CO 2 . Rat trigeminal ganglia cells were isolated and dispersed as described (17) . Rat trigeminal glial cultures were prepared as described (14) , with minor modifications. Ganglia were isolated from two-to three-day-old Sprague-Dawley rat pups, treated with 10 mg/ml dispase II (Invitrogen, Carlsbad, CA, USA) at 37 C for 30 minutes, then subjected to vigorous trituration with rapid pipetting, followed by centrifugation at 250 Â g for three minutes. The supernatant was transferred to a new tube and centrifuged at 500 Â g for five minutes to pellet glia. The pellet was resuspended in L-15 complete medium: L-15 with L-glutamine, 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 mg/ml), amphotericin B (2.5 mg/ml), 50 mM dextrose, 250 mM ascorbic acid, 10 ng/ml mouse 2.5S nerve growth factor (Alomone Labs, Jerusalem, Israel) and 8 mM glutathione. Cells were plated on 4 cm 2 coverslips in a six-well dish. Fresh medium was applied the following day and experiments started two days after plating.
Rat2 and NCI-H460 cells were treated with freshly prepared Aza-dC (Sigma-Aldrich, St. Louis, MO, USA) in dimethylsulfoxide (DMSO) every other day for six days. As a vehicle control, the same volume of DMSO was added (usually 2 ml in 2-ml media). Glial cultures were treated with Aza-dC every day in fresh medium for four to five days. For all cultures, TSA was added 1 day prior to RNA extraction.
Bisulfite sequencing assay
Genomic DNA was isolated from CA77 and Rat2 cells using DNeasy kit (Qiagen, Valencia, CA, USA). Cytosine-to-thymine conversion by sodium bisulfite and DNA purification were performed using EZ DNA Methylation TM Kit (Zymo Research, Orange, CA, USA). The genomic region around the CpG island was amplified with two rounds of polymerase chain reaction (PCR) testing. The first round was: 95 C, 10 minutes; 40 cycles of 94 C, 1 minute, 55 C, 30 seconds, and 72 C, 30 seconds; then 72 C, 30 seconcs. PCR primers were: sense 5'-TTGTTAAGTTTGTTTGTTTGTTTT-3', antisense 5'-TAAAAAAAAACCAAATACCTCTAA-3'.
Ten percent of the reaction was subjected to a second round for 25 cycles at the same settings, but with a new sense primer, 5'-GAGATTTAAGGGTGGGGG TAGGAG-3', and the same antisense primer. The PCR product was purified and cloned into pSC-A-amp/kan using StrataClone TM PCR Cloning Kit (StrataGen, Kirkland, WA, USA). Plasmids from individual clones were sequenced. Cytosine-to-thymine conversion efficiency was confirmed by monitoring non-CpG cytosine bases. In each cell line, there was 99.6% conversion (622 of 624 cytosine converted to thymine).
For human cell lines, TT and NCI-H460, the same procedure was performed except the PCR was: 95 C, 10 minutes; 40 cycles of 94 C, 1 minute, 59.2 C, Park et al.
1 minute, 72 C, 1 minute; then 72 C, 10 minutes. For the CpG island 1, primers were: sense 5'-GATTAATTAAGGGTATTTTAGAAGTTAGG-3', antisense 5'-CCTACCCTACCATCCATCACCTA CCTAAAC-3'. For CpG island 2, primers were: sense 5'-AGAGTTGGAAGAGTTTTTATAATTTTGGA TT-3', antisense 5'-ACTTACAATTTAAAACTAC TTATCCCTCAAT-3'.
Chromatin immunoprecipitation
The Upstate EZ ChIP TM (chromatin immunoprecipitation) instruction manual (Millipore, Billerica, MA, USA) was followed, with some modifications. Approximately 7 Â 10 6 cells or dispersed cells from 24 neonatal trigeminal ganglia were fixed with 1% formaldehyde for 10 minutes, then quenched with 125 mM glycine for 5 minutes. Cross-linked chromatin was sonicated five times (CA77 and ganglia cells) or twice (Rat2 cells) with 20-second pulses (output setting 3) at 1-minute intervals on ice (Ultrasonics, model W-375) to mostly in the 100 bp to $2 kb size range. Protein G Plus beads (sc-2002, Santa Cruz Biotech, Santa Cruz, CA, USA) were coated with 0.03% bovine serum albumin (BSA) and 0.24 ug/ul sheared salmon sperm DNA (Invitrogen) for 30 minutes at 4 C. For each ChIP sample, 50 ml coated beads was added to cross-linked chromatin extracted from 1.4 Â 10 6 cultured cells or 24 ganglia to preclear the chromatin for 2 hours at 4 C. Antibodies (10 mg, unless otherwise indicated) against histone H3 acetylated at Lys9,14 (06-599, Millipore) or rabbit IgG (sc-2027, Santa Cruz Biotech) were added to the precleared chromatin and incubated overnight at 4 C. The chromatin-antibody complex was precipitated by incubation with freshly coated beads for 2 hours at 4 C. After extensive washing, chromatin was eluted and crosslinks reversed by incubating in 190 mM NaCl at 65 C for 6 hours. The eluate was incubated at 37 C, 30 minutes with 10 mg RNase A (Fermentas, Glen Burnie, MD, USA). Proteins were removed with Proteinase K (Qiagen) at 45 C for 1 hour. DNA was purified using DNeasy Õ Blood & Tissue kit (Qiagen).
To amplify the 18-bp enhancer region, PCR reactions were: 94 C for 5 minutes; 31 cycles of 94 C, 1 minute, 61 C, 30 seconds, and 72 C, 30 seconds; 72 C, 10 minutes. Primers were: rat 18-bp (GenBank M34090.1) sense 5'-TAAGGGTGGGGGTAGGAG-3', antisense 5'-CCGCCTGCCTAAGGATTT-3', rat glyceraldehyde 3-phosphate dehydrogenase (Gapdh) promoter (GenBank AB047300.1) sense 5'-TTCAGATGCATGCTGGGAGCAAAC-3', antisense 5'-GGACACAAACAACACCCGCTGAAA-3'. PCR products were confirmed by sequencing. To quantify the signals, three independent ChIP assays were performed for CA77 and Rat2 cells with measurement of band intensity using Image J software. The no antibody control was subtracted as background. The signal was normalized to the input band obtained by amplification of 1/100 of the sheared DNA used for crosslinking.
Reverse transcription-PCR and real-time quantitative PCR
RNA was isolated using a QIAshredder column and RNeasy Mini Kit with DNase I treatment (Qiagen). For Rat2 cells: 500 ng RNA was reverse transcribed using a random primer (Applied Biosystems, Carlsbad, CA, USA). Two rounds of PCR were necessary to reliably detect CALCA RNAs. Thirty to 50% of the RT reaction was used for the first PCR, followed by 30% for a second PCR. PCR protocol was: 94 C, 5 minutes; 30 cycles of 94 C, 1 minute, 60 C, 30 seconds, and 72 C, 30 seconds; 72 C, 5 minutes. Primers were: CT/CGRP (GenBank M11597.1) exon 2 sense 5'-CCCTTTCCTGGTTGTCAGCATCTT-3', exon 3 antisense 5'-CATGCCTGGGCTGC TTTCTAAGGTT-3', CT (GenBank V01228.1) exon 4 antisense 5'-AGCATGCAGGTACTCAGATTCC CA-3'. CGRP (GenBank M11597) exon 3 sense and exon 5 antisense have been described (17) . For NCI-H460 cells: 730 ng of RNA was reversed transcribed. Fifteen percent of the reverse transcription (RT) reaction was used in a single round of PCR to detect CALCA RNAs. PCR protocol was: 95 C, 5 minutes; 40 cycles of 95 C, 1 minutes, 58 C, 30 seconds, and 72 C, 30 seconds; 72 C, 10 minutes. Primers were: CT (126 bp) (RefSeq NM_001741.2) sense 5'-CTGGAGCAGGAGCAAGAGAG-3', antisense 5'-GGGGAACGTGTGAAACTTGT-3'; CGRP (80 bp) (RefSeq NM_001033953.2) sense 5'-CTGGAG CAGGAGCAAGAGAG-3', antisense 5'-TGAGTCA CACAGGTGGCAGT-3'; b-actin (142 bp) (RefSeq NM_001101.3) sense 5'-AGAAAATCTGGCACCAC ACC-3', antisense 5'-GGGGTGTTGAAGGTCTCA AA-3'. PCR products were verified by sequencing.
For real-time quantitative PCR (Q-PCR), 500 ng DNase I-treated RNA was used for each RT reaction as described above. The Q-PCR reactions contained 10-30% of the RT reaction, 50 nM CT or CGRP primers (described above or previously reported (17)) with SYBR Green, as recommended (Applied Biosystems). For normalization, 0.03% of the RT reaction was used for Q-PCR with 18S rRNA (GenBank V0127) primers (17) . The Q-PCR protocol was 50 C, 2 minutes, 95 C, 3 minutes, then 40 cycles at 95 C, 15 seconds, 60.7 C, 30 seconds, 72 C, 1 minute. Each sample was measured in triplicate with delta-delta Ct normalization to 18S rRNA Ct values as described (17 
Immunocytochemistry
Immunostaining of rat trigeminal glial cells was done as described (14), unless noted. Two days after culturing, cells were rinsed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for 30 minutes, then permeabilized in 0.2% triton X-100 in PBS for 15 minutes at room temperature. Cells were blocked with 10% BSA in PBS for 30 minutes before overnight incubation at 4 C with mouse monoclonal anti-glial fibrillary acidic protein (GFAP) antibody (G3893, Sigma) (1 : 50 dilution) or b-tubulin III rabbit immunoglobulin G (IgG) (ab15568, Abcam, Cambridge, MA, USA) (1 : 100 dilution). For double immunostaining, anti-pro-CT rabbit IgG (ab53897, Abcam) (1 : 100 dilution) or anti-CT rabbit IgG (ab45007, Abcam) (1 : 100 dilution) was included with the GFAP antibody. All antibodies were diluted in 1.5% BSA. Negative controls without primary antibodies were done. Cells were blocked with 10% BSA for 30 minutes before 1-hour incubation with secondary antibodies fluorescein isothiocyanate (FITC)-donkey-anti-mouse (Jackson Laboratory, Bar Harbor, ME, USA) (1 : 200 dilution in 10% BSA) and RITC-donkey-anti-rabbit (Jackson Laboratory) (1 : 200 dilution in 10% BSA). Images were obtained with a confocal microscope (Zeiss) with the same detection gain settings for FITC and RITC channels.
Statistics
Student's t-test with two-tailed distribution was used for most analyses. When more than two means were compared, one-way analysis of variance (ANOVA) with Tukey's post-hoc test was used. Pearson's chi-square was used to analyze methylation profiles. Clones were assigned to one of three bins based on the number of CpG sites methylated (0-2, 3-11 or [12] [13] [14] . Expected values were obtained by multiplying the proportion of clones in a bin from the control group to the sum of observed clones of the treatment group. Degrees of freedom were calculated as (r -1)(c -1), where r and c are the number of rows and columns, respectively. A p value <.05 was considered significant.
Results
Methylation of CpG islands flanking the 18-bp enhancer region
DNA methylation was examined in both rat and human cell lines as models for CALCA expressing and non-expressing cells. The neuronal-like rat CA77 and human TT thyroid C cell lines express the CALCA gene, while the rat embryo-derived Rat2 fibroblast cell line and human non-small-cell lung cancer NCI-H460 cell line do not (19) . In the rat CALCA promoter region, we found one CpG island around the 18-bp enhancer at -1129 to -880 bp upstream of transcription start site using CpG island searcher (http://www.cpgislands.com) ( Figure 1A) . The CpG island meets the conventional criteria (26) . It is 250 bp with a 60% GþC content and an observed/expected CpG ratio of 0.6 (calculated as # of nucleotides Â # of CpG divided by # of C Â G). The methylation status of the CpG island was assessed using the bisulfite cytosine to thymine conversion method followed by sequencing. In Rat2 cells, CpG sites were mostly methylated, with some variability among clones ( Figure 1A) . In contrast, CA77 cells had nearly all CpG sites unmethylated ( Figure 1A) . The methylation frequency throughout the CpG island was approximately 70% in Rat2 cells, while below 10% in CA77 cells. Thus, hypermethylation at the 18-bp CpG island is correlated with CALCA gene silencing.
We then analyzed the human CALCA gene. Two CpG islands were identified: one at the distal promoter region (from -1833 to -891 bp upstream of transcription start site), which includes the 18-bp enhancer and the other encompassing the proximal promoter and exon 1 (from -234 to þ519 bp) ( Figure 1B) . These sites coincide with the two CpG rich regions within a previously identified CpG island (23) . Both CpG islands were highly methylated in the CALCA non-expressing non-small-cell lung cancer NCI-H460 cell line ( Figure 1B) . Hypermethylation was more pronounced at the 5' flanking region than in the exon. In contrast, the islands were unmethylated in the CALCA expressing human medullary thyroid carcinoma TT cell line ( Figure 1B) . The cell-specific pattern of CpG methylation suggests that DNA methylation could account for both rat CALCA and human CALCA gene silencing.
Histone H3 acetylation at the 18-bp enhancer
To examine histone acetylation, we performed ChIP assays with the CA77 and Rat2 cell lines. PCR amplification of the 18-bp region following immunoprecipitation with antibodies against histone H3 acetylated at Lys9, 14 (AcH3) yielded a robust signal in CA77 cells,
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but not in Rat2 cells (Figure 2A ). Control immunoprecipitations with IgG and without any antibody yielded only background signals. A similar enrichment was seen with dissociated (not cultured) rat trigeminal ganglia. Enrichment of the 18-bp enhancer with AcH3 antibodies in CA77 cells was greater than in Rat2 cells by almost eightfold (p < .05) (Figure 2A) . As a control, the ChIP assay was performed with the same DNA using primers specific for rat GAPDH promoter. Histone H3 and H4 have been reported to be hyperacetylated at the chicken GAPDH promoter (27) .
A similar signal was observed after ChIP with AcH3 antibodies in both cell lines ( Figure 2B ). These data indicate that histone H3 acetylation could also be involved in cell-specific CALCA gene expression.
Activation of Calca gene expression in Rat2 and NCI-H460 cells by inhibition of DNA methylation
We then examined the functional consequences of CpG methylation and histone acetylation states on CALCA gene silencing in rat and human cell lines. Because the . The methylation frequencies of CpG sites in NCI-H460 clones (9 and 11 for islands 1 and 2, respectively) and TT clones (11 and 8 for islands 1 and 2, respectively) were calculated as in panel A. If the sequence was not clear, the CpG from that clone was not included in the calculation (>5 clones used for all sites).
CALCA gene can produce both CT and CGRP through alternative splicing, we used primer sets to detect the common region of CT and CGRP (exons 2 and 3), CT only (exons 2 and 4), and CGRP only (exons 3 and 5) ( Figure 3A ). There was a detectable induction of CT mRNA when Rat2 cells were treated with 1 mg/ml Aza-dC to block DNA methylation ( Figure 3B ). As expected, a signal using the common region primers was also detected. When the Aza-dC concentration was increased to 10 mg/ml, CGRP mRNA could also be detected ( Figure 3B) . By contrast to demethylation, the HDAC inhibitor TSA had very little effect on CALCA expression in Rat2 cells ( Figure 3B ). Treatment with another HDAC inhibitor, sodium butyrate, also had little or no effect (not shown). Thus, DNA methylation, but not histone acetylation, appears to be a major factor controlling cell-specific CALCA gene expression in Rat2 cells.
We then tested the effect of Aza-dC (10 mg/ml) on NCI-H460 cells. Treatments were done with and without TSA (10nM). There was induction of CT mRNA by both Aza-dC alone (not shown) and the combination of Aza-dC and TSA ( Figure 3C ). There was no detectable CGRP mRNA. Thus, in both rat and human heterologous cell lines, the gene can be induced by epigenetic modifications and the primary splice product is CT mRNA.
Effects of Aza-dC and TSA on CALCA expression in glia
To expand the findings from the Rat2 cell line to a more physiological system, glial-enriched primary cultures from neonatal rat trigeminal ganglia were used. Under our culture conditions, we have previously shown that nearly all trigeminal ganglia neurons express CGRP immunoreactivity and display CALCA promoter activity in culture, but the co-cultured glia do not (16, 17) . In addition, early studies demonstrated that trigeminal ganglia neurons express CGRP, but not CT, immunoreactivity and that glia express neither peptide (9) . A very small amount of CT RNA (0.1% of CGRP) was detected from intact ganglia, although whether this was from neurons or glia was not determined. Because an inherent complication of primary cultures is cellular heterogeneity, we first estimated the purity of the glial cultures. About 70-80% of the cultured cells had a satellite glia morphology and immunoreactivity for the glial marker GFAP ( Figure 4A ). The number of neurons defined by immunoreactivity for the neuronal marker b-tubulin III varied among cultures, with a range of 5-20% of the cells.
Bisulfite conversion and sequence analysis of the 14 CpG sites in clones from freshly dissociated glia revealed a bimodal distribution pattern. Of the 12 clones, eight had relatively high methylation (12-14 methylated sites) and three had low methylation (0-2 methylated sites). Only one clone was in the intermediate range (3-11 methylated sites). Similar results were obtained from 16 clones analyzed from vehicletreated glia after five days in culture (11 high, 2 intermediate, 3 low). The low methylation clones are presumed to represent neurons, which were about 20% of the cells in these experiments. Treatment with 10 mg/ ml Aza-dC for 5 days and 10 nM TSA for the last 1 day increased the relative number of clones with intermediate methylation (10 high, 8 intermediate, 1 low). The distribution was significantly different than expected based on a chi-square comparison with vehicle treated cultures (p < .001).
The effect of Aza-dC treatment on CALCA gene expression was then measured. Glial cultures were treated with vehicle or Aza-dC for four to five days, followed by RT and Q-PCR. Both CT and CGRP mRNAs were detected in the vehicle treated cultures above background controls (see ''Methods''). CGRP expression is presumed to be from residual neurons based on immunostaining (16) . CT expression was much lower, $0.2% of CGRP RNA levels, as reported with intact ganglia (9) . Following incubation with Aza-dC, there was a dose-dependent $30-fold increase in CT mRNA compared to vehicle ( Figure 4B ). There was also increased CGRP mRNA; however, in contrast to the robust increase of CT mRNA, the CGRP increase was < threefold, independent of dose, and not statistically significant.
Because histone acetylation and DNA methylation can work in a cooperative manner (28) , we asked whether the combination of TSA and Aza-dC treatment would further increase CALCA expression in glia. In agreement with data from Rat2 cells, TSA alone did not induce the CALCA gene ( Figure 4C ). However, the CT mRNA level was greatly increased 78-fold by the combined treatment of Aza-dC and TSA ( Figure 4C) . The CGRP mRNA level was significantly increased threefold by the combination. This synergistic effect suggests that histone acetyltransferases might readily act on the CALCA gene upon DNA demethylation to enhance gene expression.
Induction of pro-CT expression in glia
Given the large increase in CT mRNA, we asked if there was a corresponding increase in peptide expression. We could not detect mature CT immunoreactivty in the Aza-dC-and TSA-treated cultures (data not shown). We reasoned that glia may not have sufficient machinery for post-translational processing of the CT precursor protein (pro-CT), so we analyzed the cultures for pro-CT by immunocytochemistry. Immunoreactivity for pro-CT was detected in both control and Aza-dC-treated cultures. While there was some variability, glia treated with the combination of Aza-dC and TSA generally had greater pro-CT immunoreactivity compared to vehicle-treated cultures ( Figure 5 ). From a random sampling of images (each with more than 10 glia), Aza-dC-and TSA-treated cultures had 11 pro-CT positive and three negative images, while DMSO-treated cultures had only three images with a pro-CT signal and nine negative images. Similarly, cultures treated with Aza-dC alone had greater pro-CT immunoreactivity (data not shown). These data indicate that Aza-dC-treated glial cells produce pro-CT.
Discussion
Epigenetic regulation is important in development, tissue-specific gene expression and disease (28) (29) (30) . In this study, we investigated whether epigenetic mechanisms underlie cell-specific CALCA gene expression. We found that CpG island methylation and histone H3 acetylation at the 18-bp cell-specific enhancer correlates with CALCA gene expression. The role of these epigenetic phenomena was tested using the DNA methylation inhibitor Aza-dC and the HDAC inhibitor TSA. While TSA failed to induce the CALCA gene, Aza-dC induced the gene in both human-and rat-cell lines and cultured glia. Interestingly, the combination of TSA and Aza-dC showed a synergistic effect on CALCA gene induction in glia. This indicates that DNA demethylation is required for the effect of histone acetylation to be manifested. This result indicates that CpG methylation around the 18-bp enhancer is a key determinant of cell-specific gene expression.
The observed splicing preference for CT over CGRP once the CALCA gene was activated in trigeminal glia is consistent with previous studies on the CT/CGRP splice choice. Transgenic mice engineered to express a metallothionein-CALCA fusion gene in all tissues had predominantly CT mRNA in non-neuronal cells, including Bergmann glia (31) . Furthermore, the Fox-1/Fox-2 proteins required for neuronal production of CGRP mRNA are not present in mouse brain glia (32, 33) . The relative abundance of pro-CT over mature CT suggests there is insufficient peptide processing machinery in glia.
CpG methylation could conceivably reduce CALCA expression by interfering with USF activation of the 18-bp enhancer. Unfortunately, a USF complex could not be reliably detected by ChIP assays (data not shown), possibly because of the weaker affinity of the non-consensus USF site in the 18-bp enhancer (18) . Nonetheless, a direct interference of USF binding, as seen with a hibernation-specific gene (34), seems unlikely since the USF site within the 18-bp enhancer does not have a consensus CpG dinucleotide. Presumably, methyl-binding proteins are recruited near the enhancer and recruit co-repressors to the CALCA gene. ChIP assays testing one candidate, MeCP2, did not detect significant binding of MeCP2 in Rat2 cells (data not shown). Future studies will be needed to examine other methyl-binding proteins and the growing list of other epigenetic silencing factors (35) .
The mechanisms controlling dynamic regulation of CpG methylation are only recently becoming understood (36) (37) (38) (39) . In some cases, extracellular signals have been identified that can induce demethylation. Perhaps best characterized is demethylation of an alternative BDNF promoter in neurons by activitydependent phosphorylation of MeCP2 (40, 41) . In addition, DNA methylation can be regulated by glucocorticoids (42) , neonatal stress (43) , vitamin D (44) and MAP kinases (45) . While the regulator of CALCA demethylation has not yet been identified, there are some clues that inflammatory signals might play a role. In sepsis and other conditions of severe inflammation and systemic infection, the CALCA gene is widely induced in tissues that do not normally express it and the predominant product is pro-CT (46) (47) (48) (49) . Pro-CT can have deleterious biological activity based on animal sepsis studies (50, 51) . Interestingly, unlike mature CT, pro-CT has recently been shown to bind the CGRP receptor as a partial agonist (52) .
Neurogenic inflammation and components of the immune system have long been implicated in migraine (53) (54) (55) (56) (57) . We speculate that neurogenic inflammation with accompanying mast cell degranulation could lead to epigenetic induction of CALCA. Recently, Edvinsson described an adult rat trigeminal ganglia organ culture that undergoes an in situ inflammatory response (58) . Under these conditions, there is induction of CGRP and pro-CT production in satellite glia (L Edvinsson, personal communication). Indeed, we also observed some glial pro-CT immunoreactivity in untreated cultures. While we did not detect induction of CT or CGRP mRNA in glia after treatment with an inflammatory cocktail (10 ng/ml lipopolysaccharide, 10 ng/ml TNFa, 10 ng/ml IL-1b for five days (data not shown)), it is possible that additional cytokines identified in the organ cultures, such as IL-6 (58), are needed, or that differences in the culture paradigms and/or tissue age may be important. To our knowledge, pro-CT has not been measured in migraineurs. Likewise, whether CGRP receptor antagonists in migraine clinical trials will prevent pro-CT actions is not known. Our findings suggest a potential mechanism by which the CALCA gene could be induced to produce pro-CT in trigeminal glia. We propose that pro-CT could be a biomarker of inflammatory activation of the trigeminal system in migraine.
